Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for advanced pancreatic cancer

Phase 1

Recruiting

• Conditions: pancreatic cancer

• Registration Number: JPRN-UMIN000012054
• Lead Sponsor: ational Cancer Center Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10-16
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

1) Grade 2 or greater peripheral neuropathy 2) Having UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 gene 3) Moderate ascites 4)Intestinal pneumonitis or pulmonary fibrosis 5) Uncontrollable diarrhea 6) Serious complications (organ failure, uncontrolled diabetes mellitus, active infection, ulcer, ileus, mental disorders, or central nervous system disorders) 8) Active double cancer 9) Pregnancy 10)Inappropriate for this study judged by the attending physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety Frequency of DLTs

Secondary Outcome Measures

Name	Time	Method
response rate, progression-free survival, overall survival, and adverse events